On the 28th of October 2011, Biocrine was featured as one of the prominent life science companies on the 92nd annual meeting of IVA. In an interview for IVA, Biocrine’s CEO Per-Olof Berggren talked about the main focus of the research; understanding of how a healthy insulin producing beta cell works, and why it does not do so in a diabetic patient.
IVA stands for IngenjörsVetenskapsAkademin, or Royal Swedish Academy of Engineering Sciences. Since it was founded in 1910, IVA has grown to host 12 departments. Each of them is based on a branch of engineering sciences, such as Electrical Engineering, Biotechnology, and Information Technologies. More than one thousand Swedish and foreign members have been elected into IVA.
The latest annual meeting took place on the 28th of October 2011. More than 700 participants were addressed by IVA’s President, Professor Björn Nilsson. The special theme of his speech was Life Sciences; The impressive progress happening in this area and how is it going to influence our lives today and tomorrow.
Biocrine’s CEO Per-Olof Berggren was interviewed by IVA as a part of a short movie shown during President Nilsson’s speech. Professor Berggren has explained how Biocrine and the Rolf Luft Center for Diabetes and Endocrinology, Karolinska Institutet, work toward a solution for diabetes. The proprietary InSight technology was discussed as a method to study molecular processes in a living organism.
To learn more about IVA, please follow the link to IVA’s home page.